Date: 2012-01-09
Type of information:
Compound: undisclosed compound
Company: Leo Pharma (Denmark) Virobay (USA)
Therapeutic area: Autoimmune diseases - Dermatological diseases
Type agreement: development
licensing
Action mechanism:
Disease: psoriasis
Details: * On January 9, 2012, Leo Pharma has announced that the company has entered into a multi-million dollar collaboration with the US biotech company Virobay to develop an oral treatment for psoriasis. Leo Pharma and Virobay have concluded an in-licensing deal to develop an oral treatment for psoriasis. The inlicensing deal concerns an undisclosed compound which has the potential to be the first on the market with its specific mode of action. The compound is currently being tested in preclinical studies. Phase I studies will be launched in Q4 2012, and testing on psoriasis patients is planned for Q1 2013.
Financial terms: The deal involves an upfront payment to Virobay of $ 7m, followed by milestone payments totaling up to $ 300m and tiered royalties.
Latest news:
